News
-
-
-
-
-
-
-
-
-
REGULATED PRESS RELEASE
Biophytis enters strategic agreement in Asia and secures $20 million for launch of Phase 3 trial in sarcopenia
Biophytis announces strategic agreement in Asia and secures $20 million for Phase 3 trial in sarcopenia, including creation of joint venture in Hong Kong and financing over 3 years -
PRESS RELEASE
17% increase in revenue in 2025, strong acceleration expected in 2026 and financing for the business secured
Fermentalg achieved a record revenue of €13.4 million in 2025, exceeding forecasts. New BioSolutions launched, aiming for €20 million revenue in 2026 and €50 million long term, with strong financial support from partner Huvepharma